This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. | Classification codes — C31 (malignant neoplasm of accessory sinuses) |
| B. | Synonyms — maxillary sinus cancer, ethmoid sinus cancer, sphenoid sinus cancer, frontal sinus cancer, sinonasal squamous cell carcinoma, sinonasal adenocarcinoma |
| C. | Adult onset — very high (mainly in people in their 50s–70s; 40s–60s for those related to occupational exposure) |
| 1. | History — history of the recognition of maxillary sinus cancer; elucidation of the link between nickel and wood dust and sinus cancer; the Weber-Ferguson incision |
| 2. | Causes — wood, leather, and nickel dust, smoking, HPV, chronic rhinosinusitis, inverted papilloma |
| 3. | Genetics — TP53, CDKN2A, EGFR, PIK3CA; molecular features of HPV-positive sinus cancer; mechanisms of undifferentiated carcinoma |
| 4. | Epidemiology — about 3% of all head and neck cancers; maxillary sinus cancer is the most common (80%); male predominance |
| 5. | Pathophysiology — chronic irritation of the sinus mucosa → squamous metaplasia → dysplasia → invasion; malignant transformation of inverted papilloma |
| 6. | Symptoms — unilateral nasal obstruction, epistaxis, facial pain and numbness, ocular symptoms (diplopia, proptosis), toothache and soft palate swelling |
| 7. | Signs — cheek swelling, proptosis, trigeminal nerve palsy, hard and soft palate swelling, cervical lymphadenopathy |
| 8. | Screening — no standard screening; regular nasal endoscopy for groups at high risk from occupational exposure; follow-up of inverted papilloma |
| 9. | Diagnosis — CT (bone), MRI (soft tissue and nerve invasion), PET-CT, endoscopic biopsy, Ohngren's line classification, TNM |
| 10. | Treatment — maxillectomy (infrastructure, total); radiation therapy; cisplatin CCRT; proton and carbon ion therapy |
| 11. | Prognosis — 5-year survival rate of squamous cell carcinoma about 35–50%; lesions above Ohngren's line are unfavorable; skull base invasion is unfavorable |
| 12. | Prevention — preventing occupational exposure, smoking cessation, active treatment of chronic sinusitis, complete excision of inverted papilloma |
| 13. | References — NCCN head and neck cancers; 10 papers on the epidemiology and treatment of sinus cancer |
Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date
| Category | Details |
|---|---|
| ICD-10 code | C31 — Malignant neoplasm of accessory sinuses |
| Subcodes | C31.0 maxillary sinus, C31.1 ethmoidal sinus, C31.2 frontal sinus, C31.3 sphenoidal sinus, C31.8 overlapping lesion of accessory sinuses, C31.9 accessory sinus, unspecified |
| Special Copayment Reduction code | V193 |
| Main histological types | Squamous cell carcinoma about 60–80%, adenocarcinoma about 10–15% (maxillary and ethmoid sinuses, related to wood dust), sinonasal undifferentiated carcinoma (SNUC), malignant melanoma, chondrosarcoma, osteosarcoma, rhabdomyosarcoma |
Paranasal sinus cancer, maxillary sinus carcinoma, ethmoid sinus carcinoma, frontal sinus carcinoma, sphenoid sinus carcinoma, sinus squamous cell carcinoma, sinus adenocarcinoma, sinonasal malignancy. In clinical practice, nasal cavity cancer (C30) and paranasal sinus cancer (C31) are often referred to collectively as 'sinonasal cancer.' Maxillary sinus cancer accounts for about 80% of all paranasal sinus cancers and is the most clinically important.
Paranasal sinus cancer is a disease with a very high frequency of adult onset, with a median age at diagnosis of 55–65 years. Occupational cancers related to wood and nickel dust are common in people in their 40s–60s. Ethmoid sinus adenocarcinoma (related to wood dust) is concentrated in men in their 50s–60s. In children, rhabdomyosarcoma sometimes occurs as a paranasal sinus malignancy.
Maxillary sinus cancer has been described clinically since the early 19th century. In 1826, Liston performed the first maxillectomy, after which surgical approaches to maxillary sinus malignancies developed. In 1933, the Weber-Ferguson incision was introduced and became the standard approach for resection of maxillary sinus cancer. The association between paranasal sinus cancer and occupational exposure was first identified in the nickel refining industry. In 1939, Bridge et al. first reported an increase in nasal and lung cancers among workers at a nickel refinery in Wales, UK, and the IARC later classified nickel (Group 1) and its compounds as carcinogens.
The association between wood dust and sinus adenocarcinoma was confirmed in ethmoid sinus adenocarcinoma as well as in studies of nasal adenocarcinoma (Acheson 1968). Exposure to leather dust was also recognized as an occupational carcinogen associated with sinonasal adenocarcinoma. Ohngren's line (an imaginary line joining the medial canthus to the angle of the mandible) was proposed by Ohngren in 1933 and is used for anatomical prognostic division of maxillary sinus cancer; lesions above this line (superoposterior) have a poorer prognosis.
In the history of treatment, combined radiation therapy and surgery became standardized from the 1970s, and the introduction of endoscopic surgical techniques in the 1990s–2000s and the application of proton and carbon ion therapy since the 2010s have gradually improved treatment outcomes for paranasal sinus cancer.
Wood dust, especially hardwood (oak, beech) dust, is the strongest occupational carcinogen for sinonasal adenocarcinoma (including ethmoid sinus adenocarcinoma) (IARC Group 1). Nickel and its compounds (nickel sulfide, nickel oxide) are associated with sinonasal squamous cell carcinoma and maxillary sinus cancer (IARC Group 1). Leather dust is also associated with sinonasal adenocarcinoma. Increased risk has also been reported with exposure to chromium (hexavalent), isopropyl alcohol, and formaldehyde.
Smoking is a risk factor for maxillary sinus squamous cell carcinoma. HPV (mainly HPV16) is detected in some sinus squamous cell carcinomas, and HPV-positive tumors may show a better treatment response. Inverted papilloma arises in the paranasal sinuses and undergoes malignant transformation to squamous cell carcinoma in about 5–10%. Chronic inflammation from chronic sinusitis and nasal polyps contributes to dysplasia of the sinus mucosa.
The molecular genetics of sinus squamous cell carcinoma is similar to that of head and neck squamous cell carcinoma. TP53 mutations, CDKN2A (p16) loss, EGFR overexpression, and PIK3CA mutations are the main drivers. HPV-positive sinus squamous cell carcinoma is characterized by loss of TP53 and RB1 function due to E6/E7 and p16 overexpression. Ethmoid sinus adenocarcinoma (wood dust-related, ITAC type) shows molecular features similar to colorectal adenocarcinoma (CDX2 and MUC2 expression, KRAS mutations), which stem from specific DNA damage patterns caused by carcinogenic chemicals in wood dust.
In sinonasal undifferentiated carcinoma (SNUC), rare molecular abnormalities such as IDH2 mutations, SMARCB1/INI1 loss, and NUT gene rearrangement (NUT midline carcinoma) have been reported, and treatment strategies may differ accordingly. Sinonasal malignant melanoma differs from cutaneous melanoma in its patterns of BRAF V600E (about 15%), KIT mutations, and NRAS mutations.
Paranasal sinus malignancies are rare cancers accounting for about 3% of head and neck cancers and less than about 0.5–1% of all malignancies. Annual incidence worldwide is estimated at about 10,000–15,000 cases. By site, the maxillary sinus is the most common at about 60–80%, the ethmoid sinus about 10–20%, and the frontal and sphenoid sinuses are rare. Men are affected about twice as often as women, with clear clustering in occupational groups exposed to wood, nickel, and leather dust.
In Korea, paranasal sinus cancer is rare, at a few hundred cases per year in national cancer registry statistics. Early detection has been increasing with recent advances in endoscopic techniques and diagnostic imaging, but cases already advanced at diagnosis (T3–T4) account for about 60–70% of the total, so the prognosis is poor. Stricter workplace environmental standards and the use of personal protective equipment to prevent occupational sinus cancer are emphasized in many developed countries.
Like nasal cavity cancer, the pathogenesis of paranasal sinus malignancies is understood as a multistep process of chronic mucosal irritation and injury → squamous metaplasia → dysplasia → invasive cancer. Because the sinuses have a relatively thin mucosal surface and limited ventilation, inhaled carcinogens (dust, chemicals) can remain in contact with the mucosa for a long time, and DNA damage accumulates in the process. In the case of wood dust, the dust particles themselves cause physical damage to the mucosa, and chemicals adsorbed onto the dust, such as coumarins, quinones, and phenols, cause DNA alkylation or oxidative damage.
Malignant transformation of inverted papilloma involves a combination of HPV infection and epithelial dysplasia, and EGFR overexpression, KRAS mutations, and TP53 mutations appear in inverted papilloma during malignant transformation. SNUC (sinonasal undifferentiated carcinoma) is an extremely aggressive cancer that lacks differentiation markers (negative for both SCC and adenocarcinoma markers) and shows specific molecular changes such as IDH2 mutations, NUT rearrangement, and SMARCB1 loss.
Maxillary sinus cancer initially resembles sinusitis symptoms (nasal congestion, purulent rhinorrhea, facial pain), so diagnosis is delayed. Characteristic symptoms that appear as it progresses include unilateral nasal obstruction (malignancy is suspected when only one side is blocked), epistaxis, facial pain or numbness (involvement of the V2 branch of the trigeminal nerve), and swelling of the cheek or periorbital area. With alveolar bone involvement, toothache, loose teeth, and upper alveolar swelling occur. Ocular symptoms (proptosis, diplopia, decreased vision) occur with involvement of the orbital floor. Swelling or ulceration of the palate (roof of the mouth) may develop.
Ethmoid sinus cancer presents with anosmia, unilateral nasal obstruction, pain around the nasal root, and medial orbital swelling. Sphenoid sinus cancer causes headache (occipital), facial nerve palsy, and ocular motility disorders (with cavernous sinus involvement). Frontal sinus cancer presents with frontal pain, frontal swelling, and swelling in the medial canthal region.
On physical examination, swelling and asymmetry of the cheek or infraorbital area, proptosis, ocular motility disorders, sensory abnormalities in the distribution of the trigeminal nerve (V1, V2), and swelling or ulceration of the hard and soft palate are observed. On nasal endoscopy, a mass or bloody mucus is seen at the maxillary sinus ostium or in the middle meatus. Cervical lymphadenopathy appears in about 15–25% of advanced paranasal sinus cancers, mainly involving the submandibular and upper jugular (Level I–II) lymph nodes. Ocular motor palsy, dense corneal opacity, and decreased vision suggest orbital invasion.
There is no standard screening test for paranasal sinus cancer in the general population. Regular nasal endoscopic surveillance is recommended for high-risk occupational groups exposed to wood, nickel, and leather dust. In patients after surgery for inverted papilloma, endoscopic follow-up at 6–12-month intervals is needed for early detection of recurrence and malignant transformation. When unilateral symptoms (unilateral nasal obstruction, bloody rhinorrhea, facial asymmetry) develop in patients with chronic sinusitis, imaging should be performed actively to rule out malignancy.
Skull base CT (bone window) is essential for evaluating sinus bone destruction, skull base invasion, orbital floor invasion, and alveolar bone invasion. MRI (contrast-enhanced) is superior to CT for evaluating the extent of soft tissue invasion, intraorbital invasion, dural invasion, cavernous sinus invasion, and perineural invasion. PET-CT is used to evaluate cervical lymph node and distant metastases.
Tissue is obtained by nasal endoscopic or CT-guided biopsy, and the histological type is precisely classified by immunohistochemistry (p16, CK7/20, CDX2, GFAP, S-100, HMB-45, SMARCB1/INI1, etc.). Ohngren's line: An imaginary line joining the medial canthus to the mandibular angle; maxillary sinus lesions above this line (superoposterior) are adjacent to critical structures (orbit, skull base, pterygopalatine fossa) and have a poorer prognosis. AJCC TNM 8th edition staging is used, with separate T classifications for the maxillary sinus and ethmoid sinus.
When curative resection is possible, surgery is the central treatment. Total maxillectomy is the standard operation for T3–T4 maxillary sinus cancer; lesions below Ohngren's line require inferior maxillectomy, and lesions above it require extended resection. Craniofacial resection is performed in collaboration with neurosurgery when the ethmoid sinus or skull base is involved. Endoscopic sinus surgery (ESS) provides resection rates equivalent to open surgery for T1–T2 lesions and selected T3 lesions, with superior preservation of function.
Adjuvant radiation therapy (60–66 Gy) is recommended after surgery for positive margins, perineural invasion, or lymph node metastasis. In unresectable advanced paranasal sinus cancer, cisplatin-based concurrent chemoradiotherapy (CCRT) is performed. Proton therapy and carbon ion therapy have the advantage of increasing tumor dose while minimizing damage to normal tissues (optic nerve, brainstem, spinal cord) compared with conventional radiation in paranasal sinus cancers near the skull base, and have been introduced in Japan, Germany, and some Korean institutions. For SNUC, cisplatin-based chemotherapy combined with radiation is the standard.
Paranasal sinus cancer is often already advanced at diagnosis, so the overall prognosis is poor. The overall 5-year survival rate of maxillary sinus squamous cell carcinoma by stage is about 60–70% for T1–T2, about 40–50% for T3, and about 20–30% for T4. Lesions above Ohngren's line (superoposterior) have a markedly lower 5-year survival rate than those below it (about 15–30% vs 40–60%). The 5-year survival rate of ethmoid sinus cancer is about 35–50%. SNUC (sinonasal undifferentiated carcinoma) is very aggressive, with a 5-year survival rate of only 20–30%. Cervical lymph node metastasis and distant metastasis markedly worsen the prognosis. HPV-positive sinus squamous cell carcinoma has a better prognosis than HPV-negative disease.
Preventing occupational exposure: In workplaces with wood, nickel, or leather dust, dust exposure is minimized with appropriate dust masks (N95 or higher), installation of local exhaust ventilation systems, and wet working methods. Compliance with occupational exposure limits (OEL): wood dust 5 mg/m³ or less (1 mg/m³ or less recommended for hardwood), nickel compounds 0.2 mg/m³ or less. Smoking cessation: reduces the risk of smoking-related sinus squamous cell carcinoma. Complete excision of inverted papilloma: early detection of recurrence and malignant transformation through regular postoperative endoscopic follow-up. Active treatment of chronic sinusitis: medical treatment and, if necessary, functional endoscopic sinus surgery (FESS).